ArticleCommunications biology2026
Ovo, an open-source ecosystem for de novo protein design.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ProteinDJ: A high-performance and modular protein design pipeline.Protein science : a publication of the Protein Society · 2026Article
- BioPipelines: Accessible Computational Protein and Ligand Design for Chemical Biologists.Computational and structural biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The protein design field is rapidly advancing, with frequent emergence of new models and pipelines for designing de novo proteins with tailored properties and functions not found in nature. However, the current tool landscape is fragmented, tools are hard to install and deploy, and require significant computational expertise to integrate into end-to-end, scalable pipelines. A particular challenge is managing many sequences, structures, and metrics for downstream testing and retrospective analysis of input parameters. To address this need, we introduce Ovo, an open-source de novo protein design ecosystem that consolidates models, workflows, data management, and interactive visualization into a scalable, infrastructure-agnostic platform. Ovo features Nextflow-based workflow orchestration, a storage layer, and both command-line and graphical interfaces that democratize scaffold design, binder design and diversification, and validation workflows. Ovo's novel ProteinQC module computes comprehensive sequence and structure descriptors, contextualizing designs against reference sets. Ovo plugins let the community add new workflows and user interfaces to accelerate adoption of emerging methods and facilitate community-driven benchmarking. Ovo lowers engineering barriers and demystifies the design process, allowing experts and non-technical users to design proteins at scale. With community-driven development, Ovo can accelerate de novo protein design and advance discovery in therapeutics and biotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.